| Latest Forum Topics / Raffles Medical Last:0.945 -- |
|
|
SingPost
|
|||
|
Secret_Squirrel
Elite |
21-Sep-2023 16:27
Yells: "Stay curious but skeptical" |
||
|
x 0
x 0 Alert Admin |
China's large aging population requires health care.
So it is ok to take their time to expand.
Don't expand too fast like China's property market.
I think they do not want to expand too fast as China suka suka change policy every now and then. Lol
|
||
| Useful To Me Not Useful To Me | |||
|
Joelton
Supreme |
18-Sep-2023 11:09
|
||
|
x 0
x 0 Alert Admin |
Raffles Medical eyes China healthcare growth but stays prudent on expansions
 
PRIVATE healthcare provider Raffles Medical Group has its eyes fixed on continuing to drive growth, even as it grapples with a slowdown in medical tourism amid the Covid-19 pandemic.
 
When Singapore shut its borders in early 2020, foreigners seeking medical help here had to be turned away. Private healthcare players who relied heavily on medical tourism turned to other avenues to get their care to overseas patients, including online consultations and delivering medication straight to patients&rsquo homes.
 
While some companies would have baulked at the sudden shift in operations, Raffles Medical took the changes in stride.
 
The company already had its RafflesConnect app in 2019, before the pandemic struck. With the means for teleconsultation in place, this became its main avenue to connect with patients, both foreign and local.
 
The group was also quick to support the Singapore government with vaccinations, step-down care and Covid-19 isolation. At its peak, the group ran 15 vaccination centres. The largest, in Changi Airport, administered up to 5,000 doses a day.
 
Now, with the pandemic largely behind the world, Raffles Medical is welcoming medical tourists back &ndash although they have not quite returned to the numbers prior to the pandemic, said Dr Loo Choon Yong, the group&rsquo s executive chairman.
 
&ldquo Quite clearly, with inflation and a strong Singapore dollar, healthcare here may not be affordable for everyone in the region,&rdquo he said.
 
In the group&rsquo s first-half earnings briefing, Dr Loo estimated that medical tourism has recovered to about 70 per cent of pre-Covid levels.
 
Medical tourists hailing from about 120 countries account for about 25 per cent of Raffles Medical&rsquo s patients. Many are recommended through word of mouth. However, Dr Loo noted that other medical hubs in the region, such as cities in Malaysia and Thailand, may draw more patients due to cheaper costs.
 
For example, one key market of patients, Indonesia, prefers Singapore for its proximity. But with higher price sensitivity among consumers, they may head slightly further to other South-east Asian cities such as Kuala Lumpur, Penang and Bangkok.
 
One way Singapore &ndash where Raffles Medical has about 80 per cent of its operations &ndash can stand out is in consistently putting out quality healthcare, particularly for procedures related to more serious illnesses.
 
&ldquo We can&rsquo t compete on price, but if you&rsquo re having a heart problem or cancer, I think you will be less price sensitive,&rdquo he said.
 
As Covid-19 activities petered out in 2022, Raffles Medical&rsquo s earnings for the first half of the year were relatively flat, edging up 0.5 per cent to S$59.9 million.
 
Analysts covering the stock noted its margins have largely normalised within expectations.
 
Covid-19 notwithstanding, the company has been profitable as required to attract investors and be sustainable in the long term, he noted. And it has also not rested on its laurels.
 
China spearheads overseas expansion
 
Despite the pandemic, Raffles Medical continued to push through its expansion plans, with its gaze fixed on China.
 
After opening a 700-bed Chongqing hospital in January 2019, the group upgraded its Beijing clinic into a hospital in 2020, doubling the space and bringing in operating theatres. In 2021, even as China was deep in its Covid-related movement restrictions, the group launched a 400-bed hospital in Shanghai.
 
&ldquo Even the government in Singapore has not built one hospital a year,&rdquo Dr Loo quipped.
 
Further down the line, Raffles Medical will be opening a Hainan hospital specialising in in-vitro fertilisation. &ldquo This way, we can send our patients from Chongqing or Shanghai (to Hainan) for the service,&rdquo he said.
 
But why China?
 
&ldquo Healthcare is all about the number of headcounts,&rdquo said Dr Loo. While Singapore&rsquo s population will increase over the years, there are bigger populations elsewhere seeking quality healthcare. And Raffles Medical can capitalise on gaps in those markets, he added.
 
For example, in China, most people head to state hospitals in cities for their healthcare needs. This results in a high load of patients, and doctors have &ldquo very little time to even chitchat&rdquo , he said.
 
&ldquo Some people want to have more than a three-minute consultation and will look to private care like us, which is more personalised and responsive.&rdquo
 
In terms of healthcare markets, China has also been easier to enter. For example, India, its peer in terms of population size, already boasts strong hospital players.
 
China has been key to Raffles Medical&rsquo s expansion plans since nearly a decade ago. The group was close to opening a clinic business in Shanghai at the time, but the project was canned by the government then.
 
Instead of rushing ahead with a less-ideal location, the group was patient, combing through sites until it settled on its current location in Shanghai. It now has seven hospitals and clinics in China and Hong Kong.
 
Despite the push into China, the company is not in a race to grow, said Dr Loo. Instead, it prefers to slowly diversify.
 
&ldquo The general trend is that you will see us expanding into different parts of Asia, but it must make sense for us,&rdquo he said. He raised the example that opening hospitals in Japan would be difficult as they have to be non-profit.
 
For now, the company will grow within its current outposts. Its Chinese hospitals started out with about 100 beds each when they first opened bed counts have slowly increased as occupancy fills up.
 
China&rsquo s reopening also bodes well, even if the economy is not quite as robust as it was pre-pandemic, Dr Loo said.
 
And should the opportunity come, the group will be ready to expand or acquire. He pointed to Raffles Medical&rsquo s net cash and cash equivalents, which stand at S$299.6 million as at Jun 30, as well as its increasing management and clinical strengths &ndash all contributing to a greater capacity for growth.
 
&ldquo Looking back over the past 47 years, we have been growing non-stop. So why should we stop now?&rdquo
|
||
| Useful To Me Not Useful To Me | |||
|
|
|||
|
Peggy2019
Member |
23-Aug-2023 10:57
|
||
|
x 0
x 0 Alert Admin |
Quoted from Wall Street Journal today: An Intrinsic Calculation For Raffles Medical Group Ltd (SGX:BSL) Suggests It' s 30% Undervalued   Key Insights
|
||
| Useful To Me Not Useful To Me | |||
|
bamboo300306
Veteran |
22-Aug-2023 20:54
|
||
|
x 0
x 0 Alert Admin |
Ang Mio media keeping talking down China everyday . RM has two hospital in China that why get sell down. Good entry point, just average downnif it touch 1.1 | ||
| Useful To Me Not Useful To Me | |||
|
Peggy2019
Member |
22-Aug-2023 15:50
|
||
|
x 0
x 0 Alert Admin |
Raffles Medical' s share price had fallen so much. With  a cash reserve of $207.7 million in hand, this company didn&rsquo t even come out to buy back their own shares &ldquo to save the market&rdquo . They must be planning a big move. So don&rsquo t be panic. Stay calm and confident. | ||
| Useful To Me Not Useful To Me | |||
|
|
|||
|
Joelton
Supreme |
03-Aug-2023 12:47
|
||
|
x 0
x 0 Alert Admin |
Raffles Medical' s 1HFY2023 results likely to have set a new baseline of profitability, analysts keep ' buy'
 
Analysts at CGS-CIMB Research, Maybank Securities and RHB Bank Singapore have kept their &ldquo add&rdquo and &ldquo buy&rdquo calls on Raffles Medical Group BSL 0.76% following its 1HFY2023 ended June results announcement.
 
Raffles Medical is Maybank&rsquo s preferred pick in the healthcare sector. However, analyst Eric Ong highlights that the company&rsquo s 1HFY2023 turnover fell 9.5% y-o-y to $370.9 million, mainly due to fewer Covid-19 related activities especially PCR test and diagnostic revenues.
 
&ldquo That said, the return of foreign patients seeking high-end medical treatments in Singapore saw external revenue from its hospital services division rise 8.3% y-o-y to $139.8 million,&rdquo says Ong.
 
RHB&rsquo s Shekhar Jaiswal notes that foreign patient load has only returned to 70% to 80% of the pre-Covid-19 level. This is due to a lower number of patients from China and a stronger Singapore dollar, which could be dissuading the return of some cost-sensitive patients, he adds.
 
&ldquo The decline in workforce costs due to the reduction of Covid-19 related activities is now well accounted for, implying that margins are normalising,&rdquo says Jaiswal.
 
For Raffles Medical&rsquo s China operations, turnover have &ldquo recovered nicely&rdquo by 16.2% y-o-y to $28.8 million in 1HFY2023, says Ong. In its update, the company says normal activities have resumed in the country, although it noted that its Shanghai hospital seems to be doing better than Chongqing given a larger pool of expatriates there.
 
Raffles Medical&rsquo s net cash position grew to $207.7 million in 1HFY2023 from $157 million in FY2022, even after paying out $70.7 million in dividends during the period. This allows the company to keep a lookout for potential investment opportunities while generating positive net finance income of $1.7 million in 1HFY2023, notes CGS-CIMB analyst Tay Wee Kuang.
 
To this end, Raffles Medical has shared that it is exploring mergers and acquisition opportunities across the region &mdash in countries such as Vietnam, Indonesia and Cambodia &mdash that could synergise with its core healthcare business. It is also not averse to exploring other means to deploy its cash, such as share buybacks and special dividends, Tay points out.
 
Meanwhile, Raffles Medical&rsquo s contract to operate the Changi Expo transitional care facility (TCF) has been extended for a few months as the tendering process is still ongoing. It will not only participate in the retendering process for the current TCF, but will also bid for any other TCF facilities that gets offered by the government for management, Jaiswal highlights.
 
CGS-CIMB has lifted its target price for Raffles Medical to $1.77 from $1.75 previously after it raised the company&rsquo s FY2023 to FY2025 EPS estimates by 4.8% to 10.5% to reflect stronger revenues and finance income. This will translate into a new semi-annual net profit run rate of about $60 million, almost double the FY2017-FY2019 average of about $34 million.
 
The RHB and Maybank analysts have kept their target prices at $1.75 and $1.65 respectively.
|
||
| Useful To Me Not Useful To Me | |||
|
Joelton
Supreme |
01-Aug-2023 10:55
|
||
|
x 0
x 0 Alert Admin |
Raffles Medical H1 profit rises 0.5% to S$59.9 million chairman says will consider M& A 
RAFFLES Medical Group : BSL +4.48% posted a 0.5 per cent rise in net profit to S$59.9 million for its first half ended Jun 30, from S$59.5 million in the previous corresponding period.
 
The growth in profit came despite a 9.5 per cent decline in revenue &ndash to S$370.9 million from S$409.7 million in the year-ago period.
 
Manpower costs fell alongside Covid-related activities, the private healthcare provider said on Monday (Jul 31). The group also recorded a year-on-year fall in net reinsurance expenses, and a smaller impairment loss on trade receivables.
 
These were partially offset by higher expenses for purchased and contracted services, and a small increase in operating lease expenses.
 
Earnings per share stood at S$0.0322 for the half year, up from S$0.0320 in the year before.
 
Dr Loo Choon Yong, executive chairman of Raffles Medical Group, noted in a media briefing that the group&rsquo s reported topline was still above that of the pre-pandemic level.
 
In H1 2019, Raffles Medical reported revenue of S$255.3 million.
 
Dr Loo said that although the group&rsquo s Covid-19 operations are winding down, Raffles Medical continues to provide care in transition-care facilities that were set up during the pandemic &ndash to ease patient load in the public hospitals.
 
In China, it has expanded its medical services over the last three years. It refurbished its Beijing clinic into a hospital in 2020, and opened a hospital in Shanghai in 2021.
 
The lifting of movement restrictions in China this year meant H1 revenue for the company&rsquo s China operations rose 16.2 per cent to S$28.8 million.
 
The resumption of regular flights at Hong Kong International Airport also bodes well for Raffles Medical&rsquo s airport outlet, with passengers, cabin crew and airport staff returning to work, said Dr Loo. 
 
Medical tourism has recovered to about 70 per cent of pre-Covid levels, said Dr Loo. The somewhat-muted level may be due to some foreign patients preferring not to travel for treatment, as they turned to medical care in their home countries during the pandemic.
 
Another factor he cited was the growing competition from less-expensive medical hubs in the region, such as Bangkok, Kuala Lumpur and Melaka rising costs and a strong Singapore dollar have made treatment in Singapore relatively expensive. 
 
&ldquo Quite a lot of middle-class (patients) from Jakarta and eastwards used to come to Singapore exclusively. But I think they are beginning to find Kuala Lumpur as a viable alternative,&rdquo he said. And the languages spoken there are similar to those spoken in Indonesia and Singapore.
 
He nonetheless believes Singapore will continue to occupy the higher end of the market people choose to come here for treatment because of the Republic&rsquo s stronger regulatory framework. 
 
On the group&rsquo s expansion plans, Dr Loo said Raffles Medical will increase capacity in its current hospitals and expand its cadre of specialists to serve more patients. He did not rule out acting on &ldquo compelling&rdquo opportunities.
 
Pointing to the company&rsquo s cash and cash equivalents of S$299.6 million as at Jun 30, he said: &ldquo We have the means to expand or acquire more hospitals and healthcare businesses. We are looking, and we&rsquo ll see what happens.&rdquo
|
||
| Useful To Me Not Useful To Me | |||
|
TANPK123
Elite |
31-Jul-2023 08:43
|
||
|
x 0
x 0 Alert Admin |
Woooo 1% increased only. 60.4mil. Good or bad ? | ||
| Useful To Me Not Useful To Me | |||
|
|
|||
|
mgrow2013
Member |
28-Jun-2023 19:13
|
||
|
x 0
x 0 Alert Admin |
Hope a boost will come soon 🙏 | ||
| Useful To Me Not Useful To Me | |||
|
bamboo300306
Veteran |
13-Jun-2023 19:59
|
||
|
x 0
x 0 Alert Admin |
You never go wrong with well run medical stock. Current PE is 17 which is attractive with 3% yield. Bought some today.. Will continue to average down if it go below 1.3. | ||
| Useful To Me Not Useful To Me | |||
|
superstartup
Supreme |
13-Jun-2023 17:08
Yells: "Enjoy doing Fundamental Research" |
||
|
x 0
x 0 Alert Admin |
Yep. Lousy call. I cut today, at closing.
|
||
| Useful To Me Not Useful To Me | |||
|
msksmsks
Supreme |
13-Jun-2023 16:40
|
||
|
x 0
x 0 Alert Admin |
Recent call fm UOBKH on RM and Delfi all under water.   |
||
| Useful To Me Not Useful To Me | |||
|
|
|||
|
bamboo300306
Veteran |
13-Jun-2023 16:38
|
||
|
x 0
x 0 Alert Admin |
We can take these FOC reports as reference. Currently under selling pressure... average down at this price to ride thru the volatility. At current price we should see some buy back before the next fana iCal announcement. It is a well run company, only risk is the venture isn China. if it start showing result, then the price will appreciate over time. . | ||
| Useful To Me Not Useful To Me | |||
|
superstartup
Supreme |
09-Jun-2023 15:05
Yells: "Enjoy doing Fundamental Research" |
||
|
x 0
x 0 Alert Admin |
RHB 8 June 2023 - Raffles Medical BUY target price $1.70 https://sginvestors.io/analysts/research/2023/06/raffles-medical-group-rhb-securities-research-2023-06-08 | ||
| Useful To Me Not Useful To Me | |||
|
superstartup
Supreme |
08-Jun-2023 15:15
Yells: "Enjoy doing Fundamental Research" |
||
|
x 0
x 0 Alert Admin |
For a start, someone stack 800k shares at 1.40 That' s the first initial target price ? |
||
| Useful To Me Not Useful To Me | |||
|
superstartup
Supreme |
08-Jun-2023 14:54
Yells: "Enjoy doing Fundamental Research" |
||
|
x 0
x 0 Alert Admin |
UOB KH Regional Morning Notes Thursday, 08 June 2023 STRATEGY &ndash SINGAPORE To Indonesia Via Singapore Indonesia&rsquo s economic performance has been strong on a ytd basis with the rupiah outperforming its regional peers, thus resulting in the JCI outperforming its peers in US dollar terms. We highlight various sectors and stocks listed on the SGX that could benefit from this strength with our top picks being Delfi, Marco Polo Marine and Raffles Medical.  Delfi BUY 1.29    Target 1.71 Marco Polo Marine HOLD 0.051    Target 0.04 Raffles Medical BUY 1.34    Target 1.9   |
||
| Useful To Me Not Useful To Me | |||
|
superstartup
Supreme |
08-Jun-2023 14:48
Yells: "Enjoy doing Fundamental Research" |
||
|
x 0
x 0 Alert Admin |
43% upside from current price to UOB Alpha Portfolio, Raffles Medical target price
|
||
| Useful To Me Not Useful To Me | |||
|
superstartup
Supreme |
08-Jun-2023 08:53
Yells: "Enjoy doing Fundamental Research" |
||
|
x 0
x 0 Alert Admin |
UOBKH adds Raffles Medical and ThaiBev to alpha picks drops Singtel, Food Empire and Aztech - June 23Raffles Medical is set to benefit from the Transitional Care Facilities (TCF) inclusion into Singapore&rsquo s healthcare ecosystem. With healthy margins due to its asset-light nature, contributing nearly 40% of the company&rsquo s operating profit, the TCF will help support Raffles Medical&rsquo s profit for 2023 and 2024, analyst Llelleythan Tan point out.Target Price $1.90   |
||
| Useful To Me Not Useful To Me | |||
|
MambaFinancial89
Veteran |
14-Apr-2023 11:42
Yells: "Be greedy when others are fearful. " |
||
|
x 0
x 0 Alert Admin |
CLSA raise RFMD tgt px to $2.12 from $1.92 Raffles Medical - BUY (A dose of confidence) Despite its recent share price rise, Raffles Medical (RFMD) still has room to re-rate, in our view, and we lift 23/24CL NP by 20%/23% to reflect stronger EPS growth. Healthcare sector developments suggest private operators such as RFMD could play a greater role in addressing supply issues in public hospitals, and it is already working on initiatives such as the Emergency Care Collaboration (ECC) and the Transitional Care Facility (TCF) at Connect@Changi. This public-private partnership could strengthen given Singapore&rsquo s ageing population. One risk is that RFMD opts to expand aggressively in the region, which may incur higher-than-expected startup costs. We raise our target price from S$1.92 to S$2.12 and maintain our BUY rating. |
||
| Useful To Me Not Useful To Me | |||
|
HopeToBeRight
Member |
06-Apr-2023 09:21
Yells: "My only purpose is to make money with everyone" |
||
|
x 0
x 0 Alert Admin |
Hmm ... looks special today on tops volumes. 3.8 cents dividends incoming maybe | ||
| Useful To Me Not Useful To Me | |||

